Approval of Radiopharmaceutical 'Prostaview Injection' for Prostate Cancer Diagnosis
Approved as the 43rd Domestically Developed New Drug by the Ministry of Food and Drug Safety
The Ministry of Food and Drug Safety announced on May 4 that it had approved the domestically developed new drug "Prostaview Injection (Florastamine (18F))" on April 30.
As a result, Prostaview Injection has been designated as the "43rd new drug developed in Korea."
This drug is a radiopharmaceutical used for lesion diagnosis in prostate cancer patients. It selectively binds to the prostate-specific membrane antigen (PSMA), which is highly expressed in prostate cancer, to detect lesions.
According to the "New Drug Product Approval and Review Process Guidelines" established last year, the Ministry formed a product-specific team and completed the approval process by prioritizing clinical trial (GCP) and manufacturing/quality control (GMP) reviews, as well as holding tailored face-to-face meetings.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
An official from the Ministry stated, "We expect that this drug will help establish accurate treatment directions for patients with recurrent or metastatic prostate cancer who have shown abnormal findings in existing imaging tests."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.